Regeneron obtains exclusive global rights to Sanofi’s cancer drug Libtayo
Sanofi will receive an upfront payment of $900m, 11% royalty on global sales of Libtayo, and is eligible…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Jun 22
Sanofi will receive an upfront payment of $900m, 11% royalty on global sales of Libtayo, and is eligible…
02 Jun 22
The collaboration will identify high-affinity novel antibodies against two different glycoprotein targets, where GO Therapeutics will lead the…
02 Jun 22
Pfizer said that the decision to exit from Haleon is based on its strategy to become a more…
01 Jun 22
Affinivax is engaged in developing a novel class of vaccines, including the advanced next-generation pneumococcal vaccines
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Jun 22
The US FDA approval is based on interim data from RAINBOWFISH trial, in which pre-symptomatic babies treated with…
31 May 22
The acquisition is expected to expand Evotec’s cell therapy platform EVOcells, an integrated platform for the discovery, development…
31 May 22
Cialis is a PDE-5 inhibitor therapy that can be used to treat erectile dysfunction (ED), the signs and…
30 May 22
The current FDA approval of Kymriah is based on data from the Phase 2 ELARA trial in which…
30 May 22
ViiV Healthcare and MPP are actively negotiating on terms of a voluntary licensing agreement, which would help widen…
27 May 22
The EC conditional marketing authorisation was based on the CARTITUDE-1 study, in which 98% of patients responded to…